Dr Kyle Jason Ringenberg, MD | |
988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 | |
(402) 559-4081 | |
(402) 559-7372 |
Full Name | Dr Kyle Jason Ringenberg |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 16 Years |
Location | 988102 Nebraska Medical Ctr, Omaha, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144484494 | NPI | - | NPPES |
26741 | Other | NE | NE STATE LICENSE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 26741 (Nebraska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
The Nebraska Medical Center | Omaha, NE | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Unmc Physicians | 6002728391 | 1320 |
News Archive
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
Legislators who couldn't agree this year on how to overhaul North Carolina's Medicaid program plan to spend more time talking about the issue before the General Assembly reconvenes early next year. A legislative oversight panel subcommittee charged with examining Medicaid reform and reorganization scheduled its first meeting Wednesday. Another oversight panel also examining Medicaid governance held its first meeting this month. The House and Senate approved differing versions of legislation to change how Medicaid pays for medical expenses by shifting risk from the state to either medical provider networks or private managed-care companies (9/24).
A Maryland woman traveled to the Dominican Republic early in her pregnancy, spending three weeks with family. She felt dizzy and tired and, at first, attributed the lethargy to jet lag.
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks. The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack.
› Verified 5 days ago
Entity Name | Unmc Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1417912114 PECOS PAC ID: 6002728391 Enrollment ID: O20031104000664 |
News Archive
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
Legislators who couldn't agree this year on how to overhaul North Carolina's Medicaid program plan to spend more time talking about the issue before the General Assembly reconvenes early next year. A legislative oversight panel subcommittee charged with examining Medicaid reform and reorganization scheduled its first meeting Wednesday. Another oversight panel also examining Medicaid governance held its first meeting this month. The House and Senate approved differing versions of legislation to change how Medicaid pays for medical expenses by shifting risk from the state to either medical provider networks or private managed-care companies (9/24).
A Maryland woman traveled to the Dominican Republic early in her pregnancy, spending three weeks with family. She felt dizzy and tired and, at first, attributed the lethargy to jet lag.
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks. The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Kyle Jason Ringenberg, MD 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: (402) 559-4081 | Dr Kyle Jason Ringenberg, MD 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: (402) 559-4081 |
News Archive
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
Legislators who couldn't agree this year on how to overhaul North Carolina's Medicaid program plan to spend more time talking about the issue before the General Assembly reconvenes early next year. A legislative oversight panel subcommittee charged with examining Medicaid reform and reorganization scheduled its first meeting Wednesday. Another oversight panel also examining Medicaid governance held its first meeting this month. The House and Senate approved differing versions of legislation to change how Medicaid pays for medical expenses by shifting risk from the state to either medical provider networks or private managed-care companies (9/24).
A Maryland woman traveled to the Dominican Republic early in her pregnancy, spending three weeks with family. She felt dizzy and tired and, at first, attributed the lethargy to jet lag.
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks. The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack.
› Verified 5 days ago
Stephanie Franco, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6901 N 72nd St, Omaha, NE 68122 Phone: 402-572-2121 | |
Dr. Joseph M Kalamaja, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Emile 42nd St, Omaha, NE 68198 Phone: 402-559-4081 Fax: 402-559-7372 | |
Wesley K Hubka, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7822 Davenport St, Omaha, NE 68114 Phone: 402-391-4855 Fax: 402-391-6818 | |
Dr. Cam E Enarson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2500 California Plz, Omaha, NE 68178 Phone: 402-280-5823 | |
Dr. Kimberly A Hanson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Children's Hospital - Anesthesiology, 8200 Dodge Street, Omaha, NE 68114 Phone: 402-955-4303 Fax: 402-955-4300 | |
Marvin Graves Henderson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6901 N 72 Street, Omaha, NE 68122 Phone: 402-778-9738 Fax: 402-334-2849 | |
John Ashton Heckathorn Ii, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7500 Mercy Rd Ste 1355, Omaha, NE 68124 Phone: 402-717-4866 |